Home / 2020 / June / 02

Daily Archives: June 2, 2020

WillScot to Participate in the Stifel 2020 Virtual Cross Sector Insight Conference

BALTIMORE, June 02, 2020 (GLOBE NEWSWIRE) — WillScot Corporation (“WillScot”) (Nasdaq: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will host virtual meetings with investors during Stifel’s 2020 Virtual Cross Sector Insight Conference.  The meetings are by appointment only and will take place on Tuesday, June 9th, 2020.

About WillScot Corporation

Headquartered in Baltimore, Maryland, WillScot is the public holding company for the Williams Scotsman family of companies. WillScot trades on the Nasdaq stock exchange under the ticker symbol “WSC,” and is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. WillScot is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, security and energy sectors. With over half a century of innovative history, organic growth and strategic acquisitions, WillScot serves a broad customer base from approximately 120 locations throughout the United States, Canada and Mexico, with a fleet of approximately 150,000 modular space and portable storage units.

Additional Information and Where to Find It

Additional information about WillScot can be found on its investor relations website: https://investors.willscot.com

Contact Information

Investor Inquiries:

Mark Barbalato
investors@willscot.com

Media Inquiries:

Scott Junk
scott.junk@willscot.com

FDA issues Emergency Use Authorization for Philips’ new acute care patient monitoring solutions for hospital-based remote monitoring

June 2, 2020

  • Philips’ IntelliVue Patient Monitors MX750/MX850, IntelliVue 4-Slot Module Rack FMX-4 and IntelliVue Active Displays AD75/AD85 receive FDA Emergency Use Authorization for use in the US during the COVID-19 emergency [1]
  • New acute care patient monitoring solution offers an expanded, real-time view of a patient’s vital signs for bedside and remote monitoring in the hospital       

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the US FDA has issued an Emergency Use Authorization (EUA) for Philips’ IntelliVue Patient Monitors MX750/MX850 and its IntelliVue Active Displays AD75/AD85, for use in the US during the COVID-19 health emergency [1]. These patient monitoring solutions support infection-control protocols and remotely provide critical patient information for caregivers, capabilities that are much needed when caring for hospitalized COVID-19 patients.

Philips’ IntelliVue Patient Monitors MX750/MX850 and IntelliVue Active Displays AD75/AD85 received CE mark in 2019 and are already being used in hospitals across Europe. The EUA allows Philips to start delivering the new remote patient monitoring solution to hospitals in the US, and the company is committed to submitting a 510(k) to FDA for this acute care solution in the course of 2020.

As countries across the globe continue to combat COVID-19, while gradually resuming elective care, Philips is significantly increasing its patient monitor production to address the demand for increased Intensive Care Unit (ICU) capacity. Hospitals and health systems are increasingly relying on health technology to better manage the influx of COVID-19 patients they are seeing in Emergency Rooms (ERs) and ICUs. To minimize staff exposure to the virus that causes COVID-19 while still delivering quality care, there is a critical need for patient monitors that enable clinicians to remotely monitor a patient’s condition.

“As the world continues to battle against COVID-19, we’re committed to ramping up production of all critical solutions that can help in this time of crisis,” said Peter Ziese, General Manager, Monitoring and Analytics at Philips. “This FDA EUA for our MX750 and MX850 monitors and IntelliVue AD75 and AD85 Active Displays allows us to do that for these remote patient monitoring solutions, which are of vital need in the ICU. At Philips, being able to provide the right information at the right time to caregivers has always been a top priority. Now more than ever, there’s an urgent need to make sure those on the frontline have all the available resources at their disposal.”

The IntelliVue Patient Monitors MX750/MX850 and IntelliVue Active Displays AD75/AD85 offer advanced functionality and clinical decision support capabilities such as Philips’ IntelliVue Horizon Trends information view, which shows deviations in vital signs (for example, CO2 and heart rate) to contextualize a patient’s condition, while also supporting infection-control protocols and access to key information both remotely and at the bedside. Features such as Philips’ Alarm Advisor and Alarm Reporting help to reduce alarm fatigue for caregivers, while the smooth glass surfaces, rounded edges and special surface material of the monitors and displays facilitates cleaning and disinfection.

The MX750 and MX850 monitors are the latest additions to Philips’ portfolio of integrated patient monitoring solutions to support improved clinical and operational workflows. The MX750 and MX850 also include updated features, including enhancements to monitor and assess clinical and network device performance, and additional functionalities to strengthen cybersecurity.

For more information on how Philips is addressing COVID-19 globally, please visit the Philips centralized COVID-19 hub.

[1]   The status of the Emergency Use Authorization can be found on the FDA website.
·The IntelliVue Patient Monitors MX750/MX850, IntelliVue 4-Slot Module Rack FMX-4 and IntelliVue Active Displays AD75/AD85 have neither been FDA cleared or approved for the indication to assist in for monitoring and recording of, and for generating alarms for, multiple physiological parameters of adult, pediatric, and neonate patients having or suspected of having Coronavirus-2019 (COVID-19)
·The IntelliVue Patient Monitors MX750/MX850, IntelliVue 4-Slot Module Rack FMX-4 and IntelliVue Active Displays AD75/AD85 have been authorized for the above emergency use by FDA under an EUA
·The IntelliVue Patient Monitors MX750/MX850, IntelliVue 4-Slot Module Rack FMX-4 and IntelliVue Active Displays AD75/AD85 have been authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of medical devices under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

For further information, please contact:

Steve Klink
Philips Global Press Office
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

Kathy O’Reilly
Philips Global Press Office
Tel.: + 1 978-221-8919
E-mail: kathy.oreilly@philips.com
Twitter @kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

New USB3 cameras engineered to meet the challenges of modern vision systems

Teledyne Lumenera expands its Lt Series camera portfolio with new compact and lightweight USB3 cameras for use in diverse imaging applications

Teledyne Lumenera Lt Series USB3 Cameras

The Lt Series USB3 Cameras are designed to meet the challenges of today’s imaging applications

OTTAWA, June 02, 2020 (GLOBE NEWSWIRE) — Teledyne Lumenera, a Teledyne Technologies [NYSE:TDY] company, and manufacturer and developer of digital cameras for industrial and scientific imaging applications, is pleased to announce the release of its new Lt Series USB3 cameras. With robust compact enclosures and fully-locking USB3 connectors, these new cameras are built for rugged 24/7 use. Equipped with the latest rolling shutter Starvis™ CMOS sensors and global shutter Pregius™ CMOS sensors from Sony®, and ranging in resolution from 2-20 megapixels, these new cameras perform in a wide variety of imaging applications such as aerial imaging, Intelligent Traffic Systems (ITS), robotic inspection solutions, and life sciences. Teledyne Lumenera’s Lt Series Cameras offer a smaller, lighter, and lower cost imaging solution and are designed specifically to meet the challenges of today’s modern imaging systems that strive to provide advanced vision performance while using less power, less space, and fitting increasingly tight industry budgets.

“Even with a more compact form factor, the new Lt Series cameras offer the full set of features that the modern imaging industry demands,” said Ghislain Beaupré, General Manager at Teledyne Lumenera. “These new cameras open up new opportunities for imaging system designers to incorporate full-function cameras without unnecessary performance compromises due to size.”

The Teledyne Lumenera Lt Series Cameras offer proven 32 and 64-bit operating system compatibility for, Windows, Linux, Linux for embedded system platforms, and single board computers (SBCs). They are designed to deliver high dynamic range, high speed, with low read noise for both industrial and scientific imaging applications.

Key Features:

  • Thirteen new USB3 cameras will range in resolution from 2 – 12 MP with additional resolutions following
  • High sensitivity (pixel sizes from 2 μm to 3.45 μm) with back illuminated sensors
  • Compact form factor simplifying integration in modern OEM solutions
  • Side mounted locking industrial micro USB for power and control
  • Region of Interest (ROI) option to provide higher frame rates
  • Multiple data rates supported, each optimized for lowest noise performance
  • USB3 Vision compliant, with Windows and Linux SDKs
  • 3-year warranty

For more information about Teledyne Lumenera’s Lt Series USB3 cameras visit the website.

Teledyne Lumenera, part of the Teledyne Imaging Group, is headquartered in Ottawa, Canada, and is a leading developer and manufacturer of high-performance digital cameras and custom imaging solutions. Teledyne Lumenera imaging solutions provide a unique combination of speed, resolution, and sensitivity to meet the most demanding digital imaging requirements, and deployed worldwide in a wide range of industrial and scientific applications. For additional information about Teledyne Lumenera, please visit www.teleddynelumenera.com or call 613-736-4077. To receive Teledyne Lumenera news releases when they are issued, contact us at lumenera.marketing@teledyne.com.

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers world-wide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage.

All trademarks are registered by their respective companies.
Teledyne Lumenera reserves the right to make changes at any time without notice.

Contact:
Brooks Riendeau, Vice President of Marketing
613-736-4077 ext. 120
brooks.riendeau@teledyne.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1d2de67a-a468-4454-a86c-6e8ad2316042

OKEx Expects 100% Increase in Staff in Two Years

MALTA, June 02, 2020 (GLOBE NEWSWIRE) — In the aftermath of the COVID-19 epidemic, amidst global economic downturns and rising unemployment rates, the crypto industry has been gaining great tractions – the total number of confirmed transactions per day, according to Blockchain.com, has been steadily growing since the dramatic drop of BTC in March to around 250K transactions per day; while the total trading volume on major Bitcoin exchanges has reached USD 684.4M in March. The COVID-19 pandemic undoubtedly accelerated the adoption of crypto, encouraging more people to grow trust in Bitcoin over traditional safe-haven like gold, stock market, and real estate.

Considering the growing business opportunities and the increasing demand of crypto trading, OKEx is expanding its presence to different regions of the world beyond the existing 180 countries and areas. “This is an exciting time for OKEx, we plan to open new offices in more regions to better serve our users, and we’ve already started recruiting passionate blockchain professionals to grow and prosper together. We expect a 100% increase in the total number of staff in 2 years serving customers from around the world,” said Jay Hao, CEO of OKEx.

Jay also shared that OKEx is launching a Beacon Program in the European regions to support those who are interested in the thriving world of blockchain and crypto in the times of lockdown, which also serves as an opportunity to nurture potential talents for OKEx.

The OKEx Beacon Program will recruit a total of 6 mentees for a one-month exclusive mentorship with CEO Jay Hao and Director of Financial Markets Lennix Lai. Once in a week, mentees get to join a 30-minute mentoring session on Telegram. In addition, they will also participate in masterclasses given by industry professionals on a specific topic in blockchain and crypto, be shared with daily news digest, industry researches, and product knowledge every day and be guided through by the OKEx team, and outstanding performers will get the chance to join the OKEx team in the future.

About OKEx

The world’s largest and most diverse cryptocurrency marketplace, OKEx is where global crypto traders, miners, and institutional investors come to manage crypto assets, enhance investment opportunities, and hedge risks. We provide spot and derivatives trading, including futures, perpetual swap, and options, of major cryptocurrencies, offering investors great flexibility in formulating their strategies to maximize gains and mitigate risks.

Media Contact
Vivien Choi
media@okex.com

WillScot Announces Upsizing And Pricing of $650 Million Senior Secured Notes Offering

BALTIMORE, Md., June 02, 2020 (GLOBE NEWSWIRE) — WillScot Corporation (Nasdaq: WSC) (“WillScot”), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that its indirect subsidiary Picasso Finance Sub, Inc. (the “Issuer”) has priced its offering of $650 million in aggregate principal amount of 6.125% senior secured notes due 2025 (the “Notes”). WillScot upsized the offering size opportunistically from $500 million to $650 million. WillScot intends to use the offering proceeds, together with funds drawn under WillScot’s fully committed $2.4 billion ABL credit facility, to be entered into at the closing of the Merger (as defined below), to repay all outstanding indebtedness under its existing ABL Facility and Mobile Mini, Inc.’s (“Mobile Mini”) existing ABL Facility, redeem all of Mobile Mini’s outstanding senior notes, and redeem all of Williams Scotsman International, Inc.’s (“WSII”) senior secured notes due 2022 (collectively, the “Refinancing Transactions”), in connection with WillScot’s pending merger with Mobile Mini (the “Merger” or the “Proposed Transaction”), and to pay fees and expenses related to the Refinancing Transactions and the Merger.

The Issuer, a wholly-owned subsidiary of WSII, was formed to issue notes to facilitate the Refinancing Transactions in connection with the Merger. If the offering is consummated, the initial purchasers will deposit the gross offering proceeds into an escrow account. Upon consummation of the Merger and the satisfaction of other conditions, the escrowed proceeds will be released to complete the Refinancing Transactions and pay fees and expenses related to the Refinancing Transactions and the Merger. Upon the closing of the Merger, the Issuer will also merge with and into WSII, with WSII continuing as the surviving corporation, and WSII will assume the obligations of the Issuer under the Notes and the indenture governing the Notes. If the Merger is not completed by a specified date or certain other events occur, the Notes will be subject to a special mandatory redemption.

The Notes are being offered in a private placement transaction to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States in accordance with Regulation S under the Securities Act. The Notes will not be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This press release does not constitute an offer to sell any security and shall not constitute an offer to sell or the solicitation of any offer to buy any security in any jurisdiction in which such offer or solicitation would be unlawful.

WillScot expects the offering to close on June 15, 2020, subject to customary closing conditions.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements relate to the Proposed Transaction involving WillScot and Mobile Mini, including: expected scale; operating efficiency; stockholder, employee and customer benefits; key assumptions; timing of closing; the amount and timing of revenue and expense synergies; future financial benefits and operating results; and integration spend, which reflects management’s beliefs, expectations and objectives as of the date hereof. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Although WillScot believes that these forward-looking statements are based on reasonable assumptions, it can give no assurance that any such forward-looking statement will materialize. Important factors that may affect actual results or outcomes include, among others, our ability to acquire and integrate new assets and operations; our ability to achieve planned synergies related to acquisitions; our ability to manage growth and execute our business plan; our estimates of the size of the markets for our products; the rate and degree of market acceptance of our products; the success of other competing modular space and portable storage solutions that exist or may become available; rising costs adversely affecting our profitability (including cost increases resulting from tariffs); potential litigation involving our company; general economic and market conditions impacting demand for our products and services; implementation of tax reform; our ability to implement and maintain an effective system of internal controls; and such other risks and uncertainties described in the periodic reports we file with the SEC from time to time (including our Form 10-K for the year ending December 31, 2019 and our Form 10-Q for the quarter ended March 31, 2020), which are available through the SEC’s EDGAR system at www.sec.gov and on our website. Any forward-looking statement speaks only at the date on which it is made, and WillScot disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Important Information About the Proposed Transaction

In connection with the Proposed Transaction, WillScot filed a registration statement on Form S-4 (No. 333-237746), originally filed on April 17, 2020, which includes a prospectus of the Company and a joint proxy statement of the Company and Mobile Mini (the “joint proxy statement/prospectus”). The registration statement was declared effective by the SEC on May 5, 2020, and WillScot and Mobile Mini commenced mailing the joint proxy statement/prospectus on or about May 8, 2020. Each party will file other documents regarding the Proposed Transaction with the SEC. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain these documents (if and when available) free of charge from the SEC’s website at www.sec.gov. The documents filed by the Company with the SEC may also be obtained free of charge from the Company by requesting them by mail at WillScot Corporation, 901 S. Bond Street, Suite 600, Baltimore, Maryland 21231. The documents filed by Mobile Mini may also be obtained free of charge from Mobile Mini by requesting them by mail at Mobile Mini, Inc. 4646 E. Van Buren Street, Suite 400, Phoenix, Arizona 85008.

Participants in the Solicitation

WillScot, Mobile Mini, their respective directors and executive officers and other members of management and employees and certain of their respective significant stockholders may be deemed to be participants in the solicitation of proxies in respect of the Proposed Transaction. Information about WillScot’s directors and executive officers is available in WillScot’s proxy statement, dated March 20, 2020, as supplemented by the supplement dated April 13, 2020, for the 2020 Annual Meeting and WillScot’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on March 2, 2020. Information about Mobile Mini’s directors and executive officers is available in Mobile Mini’s proxy statement, dated March 16, 2020 as supplemented by the supplement dated April 10, 2020, for its 2020 Annual Meeting of Stockholders and Mobile Mini’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on February 3, 2020. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holding or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the Proposed Transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the SEC, WillScot or Mobile Mini as indicated above.

No Offer or Solicitation

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Contact Information

Investor Inquiries:

Mark Barbalato
investors@willscot.com

Media Inquiries:

Scott Junk
scott.junk@willscot.com

Toronto centre solving cell manufacturing challenges to benefit patients and global industry

CCRM and Cytiva, formerly part of GE Healthcare Life Sciences, renew collaboration agreement for Centre for Advanced Therapeutic Cell Technologies

TORONTO and MARLBOROUGH, Mass., June 02, 2020 (GLOBE NEWSWIRE) — With Health Canada and the Food and Drug Administration beginning to approve and reimburse cell and gene therapies in significant numbers, the demand for cell and viral vector manufacturing will continue to grow. Consequently, the industrialization challenges associated with the variability of cell and gene therapies, and with manufacturing them on a commercial scale, must be overcome. CCRM and Cytiva, formerly part of GE Healthcare Life Sciences, have renewed their Collaboration Agreement for continued operation of the Centre for Advanced Therapeutic Cell Technologies (CATCT), which was created to accelerate the development and adoption of cell manufacturing technologies for novel regenerative medicine-based therapies.

“Together, CCRM and Cytiva have established a commercialization hub where great minds, state-of-the-art equipment and a spirit of innovation meet,” says Michael May, President and CEO of CCRM. “Continuing to partner in the operation of CATCT will enable us to move the cell and gene therapy industry closer to fulfilling its promise of creating cures, and enabling treatments to get to patients.”

“By creating an innovative platform and approach to tackle the issues facing commercialization of living therapies, we are supporting the viability of the regenerative medicine industry,” says Catarina Flyborg, Vice President, Cell & Gene Therapy, Cytiva. “In CATCT, we are creating the technologies, processes and equipment that will enable our customers, and the broader industry, to achieve its goals and help patients.”

Established in 2016, CATCT is a partnership between CCRM and Cytiva, with initial funding from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). Its staff of 40 works in a 10,000 ft² (~930 m²) process development facility, located in the MaRS Discovery District, next to Toronto’s world-leading hospitals and the University of Toronto.

The global regenerative medicine market was valued at US$23.8 billion (2018), and it is anticipated to grow to US$151 billion by 2026 with an annual growth rate of 26.1 per cent.i Operating CATCT allows CCRM and Cytiva to address the manufacturing bottlenecks that would otherwise have the potential to impede the industry’s growth.

CATCT’s key areas of expertise are:

  • Immuno-oncology: CAR-T, NK, cell selection, transduction, expansion, downstream processing and cryopreservation; autologous process closure, automation and workflow design;
  • Viral vectors: Upstream production, downstream purification, formulation and workflow design;
  • Media development: Screening and de novo development of custom cell and gene therapy media;
  • Scale-up: Pluripotent stem cells, viral and allogenic scale-up and workflow design; and,
  • Analytics: Assay development, automation and qualification; flow cytometry, infectious titre, cell enumeration and functional assays.

The work conducted in CATCT can be categorized as follows: the first is fee-for-service development projects that advance customers’ therapeutic technologies towards industrialization; second, the team’s New Product Introductions (NPIs) efforts provide core biological expertise in Cytiva’s product development process; finally, internal technology development builds additional capabilities and innovative solutions for cell and gene therapies.

A recent success stemming from the work being done in CATCT is the involvement of CCRM and Cytiva in a consortium led by iVexSol Canada, with conditional funding from Next Generation Manufacturing Canada (NGen), to build an advanced manufacturing platform for lentiviral vectors. As core partners in this consortium, which was announced in August 2019, CCRM will provide supporting manufacturing infrastructure and downstream processing capabilities, and Cytiva will share expertise of manufacturing processes, and access to and use of specialized tools and technology.

The new collaboration agreement between CCRM and Cytiva has a three-year term and it became effective on October 15, 2019. The funding will be a combination of in-kind contributions, milestone payments, reinvested fee-for-service revenue and any successful grant opportunities. FedDev’s funding of CATCT was for a three-year term and ended in December 2018.

About CCRM
CCRM, a Canadian not-for-profit organization funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, strategic investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding, and infrastructure. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Toronto’s Medicine by Design. CCRM is hosted by the University of Toronto. Visit us at ccrm.ca.

About Cytiva
Cytiva is a 3.3 billion USD global life sciences leader with nearly 7,000 associates operating in 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit www.cytiva.com for more.

For more information, please contact:

Stacey Johnson
Director, Communications and Marketing, CCRM
416-946-8869
stacey.johnson@ccrm.ca

Colleen Connolly
Senior Communications Manager, Cytiva
774-245-3893
Colleen.Connolly@cytiva.com

ihttps://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

Efinix® Announces Availability of Three RISC-V® SoCs

SANTA CLARA, Calif., June 02, 2020 (GLOBE NEWSWIRE) — Efinix®, an innovator in programmable product platforms and technology, today announced availability of a series of three software defined, SoCs based on the popular RISC-V® core.

The three designs have been optimized for Efinix’s Trion® family of FPGAs and provide a range of compute and I/O capabilities in devices from the T8 to the T120. To learn more, visit: https://www.efinixinc.com/products-riscv.html.

“RISC-V is a versatile and efficient embedded compute solution,” said Mark Oliver, senior director of marketing at Efinix.  “Based on Charles Papon’s powerful and efficient VexRiscv design, our Trion® family of SoCs delivers pre-optimized RISC-V cores across the entire Trion FPGA product line from the cost optimized T8 right up to the T120.  Users can now easily create and deploy entire SoCs including embedded compute, I/O and custom functionality.”

For ease of use, the SoCs are preconfigured with a RISC-V core, memory, a range of I/O and have interfaces for embedding user functions.  In this way, designers can easily create entire systems that include embedded compute and user defined accelerators within the same FPGA.

“Since winning the RISC-V Soft CPU contest in 2018 and the Linux support addition, the VexRiscv core has been rising in popularity inside the open source community,” said Charles Papon, the designer of VexRiscv.  “Optimizing the core into pre-defined configurations on the Trion family of FPGAs will give a much larger number of designers a turnkey and cost-effective way to access the power of the core in a broad variety of system designs.”

Efinix RISC-V SoCs come with a complete set of tools for compiling and debugging application code on the RISC-V core along with example applications and tutorials.  They are compatible with the entire suite of Efinix development and evaluation boards and can be instantiated using the standard Efinity® tool flow.

About Efinix

Efinix®, an innovator in programmable products, drives the future of edge AI computing with its Trion® FPGA silicon platform. At the Trion FPGA’s core is Efinix’s disruptive Quantum™ FPGA technology which delivers a 4X Power-Performance-Area advantage over traditional FPGA technologies. Trion FPGAs, offering 4K to 200K logic elements, have a small form-factor, low-power, and are priced for high-volume production. Our Efinity® Integrated Development Environment provides a complete FPGA design suite from RTL to bitstream. With their Power-Performance-Area advantage, Trion FPGAs address applications such as custom logic, compute acceleration, machine learning and deep learning. Through Efinity, our customers can seamlessly migrate FPGA or full system into Quantum ASIC for ultra-high-volume production.

For more information, visit http://www.efinixinc.com.

Contact:

Steve Stratz

Relevanz Public Relations for Efinix

206.300.9134

steve@relevanzpr.com